Press release
Investigation announced for Investors who lost money with shares of Eyenovia, Inc. (NASDAQ: EYEN)
An investigation for investors in Eyenovia, Inc. (NASDAQ: EYEN) shares over potential securities laws violations by Eyenovia, Inc.
Investors who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Eyenovia, Inc. (NASDAQ: EYEN regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. Eyenovia, Inc. went public in January 2018.
Since then shares of Eyenovia, Inc. (NASDAQ: EYEN) declined from $10.74 per share on January 25, 2018 to as low as $3.99 per share on May 09, 2023.
Those who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Eyenovia, Inc. (NASDAQ: EYEN) here
News-ID: 3049177 • Views: …
More Releases from Shareholders Foundation
Deadline on June 10th coming up in Lawsuit for Investors in shares of Ocugen, In …
A deadline is coming up on June 10, 2024 in the lawsuit filed for certain investors of Ocugen, Inc. (NASDAQ: OCGN) over alleged securities laws violations by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN ) have certain options and there are strict and short deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to…
Investigation announced for Investors in FMC Corporation (NYSE: FMC) over potent …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of FMC Corporation.
Investors who are current long term investors in FMC Corporation (NYSE: FMC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: FMC stocks follows a lawsuit filed against FMC Corporation over…
Investigation announced for Long-Term Investors who lost money with Advance Auto …
An investigation was announced for long-term investors in shares of Advance Auto Parts, Inc. (NYSE: AAP) concerning potential breaches of fiduciary duties by certain directors of Advance Auto Parts, Inc.
Investors who are current long term investors in Advance Auto Parts, Inc. (NYSE: AAP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc.
Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its…
More Releases for Eyenovia
Myopia & Presbyopia Eye Drops Market 2028: Global Demand, Key Players, Overview, …
Myopia & Presbyopia Eye Drops Market report studies the Myopia & Presbyopia Eye Drops with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Myopia & Presbyopia Eye Drops Market analysis segmented by companies, region, type and applications in the report.
Scope of Myopia…
Myopia & Presbyopia Eye Drops Market Research Report 2022- Global Industry Analy …
The Myopia & Presbyopia Eye Drops market report offers a complete assessment. It does as such by means of inside and out subjective experiences, authentic information, and certain projections about market size. The projections included in the report have been determined utilizing demonstrated examination techniques and presumptions. Thus, the examination report fills in as a vault of investigation and data for each aspect of the market, including Regional business sectors,…
Myopia & Presbyopia Eye Drops Market is expected to exhibit a CAGR of 74.3% duri …
Myopia & Presbyopia Eye Drops Market Research focuses on the key trends prevailing in the Global Myopia & Presbyopia Eye Drops Industry sector. The existing Industry scenario has been studied and future projections with respect to the sector have also been investigated. Market study report comprises evaluation of numerous influential factors including industry overview in terms of historic and present situation, key manufacturers, product/service application and types, key regions…
Myopia & Presbyopia Eye Drops Market Size, Demand, and Global Value Expand at an …
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Myopia & Presbyopia Eye Drops Market Report that covers exclusive and analytical data through the span of seven years between 2021-2027. This report is exclusive and encompasses in-depth analysis and industry insights…
Myopia & Presbyopia Eye Drops Market Expected to Expand at a Steady 2021-2028 | …
Myopia or nearsightedness is a frequently observed eye disorder, in which a person can see objects farther away blurred, however not affecting the nearby object vision. This occurs due to the change in the eye lens shape, which leads to bending (refract) of light rays incorrectly, which causes image focusing in front of the retina instead of on the retina. Moreover, presbyopia is a condition that involves gradual loss of…
Age-related Vision Dysfunction Market Technology, Recent Trends, Future Growth A …
Common Age-Related Vision Issues Presbyopia, glaucoma, dry eyes, age-related macular degeneration, cataracts, and temporal arteritis are all common age-related eye problems. If you have diabetes, it's extremely important to keep up with frequent eye doctor appointments.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=390398
Top Key Players Included in This Report: Hoffman La Roche, Eyenovia, Allergan/AbbVie and Molecular Therapeutics, Regenxbio, Novartis, Santen, Nicox Ophthalmics, Kodiak Sciences, Opthea Limited, Ocular Therapeutix, Orasis Pharmaceuticals, IVERIC…
